Australia’s Biota Chairman, Shareholder Wage War Over GSK Suit
This article was originally published in PharmAsia News
Australia's Biota, fresh from a legal battle with GlaxoSmithKline, now faces another conflict over seating a board contender waging a shareholder revolt. Michael Montalto, a Melbourne physician, was nominated to be a board member, but Biota Chairman has vowed to use proxy votes to keep him off the panel. Montalto is a member of the Australian Shareholders Association who has cited the company's suit with GSK as the reason for his fight. He proposes canceling Biota's effort to buy back 5 percent of the company's shares. (Click here for more
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.